Deutsche Bank restated their hold rating on shares of Relx (LON:REL) in a research note published on Friday morning, ThisIsMoney.Co.Uk reports.
A number of other analysts also recently issued reports on REL. Goldman Sachs Group raised Las Vegas Sands to a buy rating in a research note on Tuesday, June 11th. UBS Group set a $54.00 target price on Westlake Chemical and gave the stock a sell rating in a report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. set a $195.00 target price on bluebird bio and gave the stock a buy rating in a report on Friday, May 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. Relx presently has an average rating of Buy and a consensus price target of GBX 1,821.50 ($23.80).
LON:REL opened at GBX 1,965.50 ($25.68) on Friday. The company has a current ratio of 0.44, a quick ratio of 0.36 and a debt-to-equity ratio of 270.50. Relx has a 1 year low of GBX 1,466.50 ($19.16) and a 1 year high of GBX 1,982.50 ($25.90). The business has a 50 day moving average price of GBX 1,905.94. The company has a market cap of $38.26 billion and a P/E ratio of 27.53.
In other news, insider Henry Udow sold 50,831 shares of Relx stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of GBX 1,759 ($22.98), for a total value of £894,117.29 ($1,168,322.61).
Relx Company Profile
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Featured Article: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.